Sheba Medical Center funds Entolimod cancer trial, opening new oncology pathway for Valion Bio

VBIO•2026-07-20

Development timeline

IRB decision targeted for Q3 2026
First patient enrollment expected Q4 2026–Q1 2027
Interim data slated for early 2027

Program targets radiation-induced neutropenia

The program targets radiation-induced neutropenia, opening a second development pathway beyond the FDA Animal Rule effort for acute radiation syndrome.

Sheba Medical Center-funded trial expands Entolimod into supportive oncology

Valion Bio disclosed a new clinical expansion for Entolimod into supportive oncology via a Sheba Medical Center-funded trial in cancer patients.

Sheba, ranked No. 7 globally, plans to run the study in up to 10 adults receiving high-dose irradiation for a rare cancer.

Sources

Sheba Medical Center funds Entolimod cancer trial, opening new oncology pathway for Valion Bio

Publicnow

Sheba Medical Center funds Entolimod cancer trial, opening new oncology pathway for Valion Bio

Development timeline

Program targets radiation-induced neutropenia

Sheba Medical Center-funded trial expands Entolimod into supportive oncology

Related News

Macerich Co <MAC.N>: Piper Sandler raises target price to $28 from $21

SL Green Realty Corp <SLG.N>: Piper Sandler Raises Target Price to $65 From $50

Clorox Company <CLX.N>: Barclays raises target price to $86 from $85

Sources

Sheba Medical Center funds Entolimod cancer trial, opening new oncology pathway for Valion Bio

Lineage Inc <LINE.O>: Piper Sandler raises target price to $46 from $35

Novartis Q2 profit up as generic competition mounts